Top

Published in:

01-01-2015 | Endocrine Tumors

Clinicopathologic Characteristics of Incidentally Identified Pheochromocytoma

Authors: Heather Wachtel, MD, Isadora Cerullo, BA, Edmund K. Bartlett, MD, Robert E. Roses, MD, Debbie L. Cohen, MD, Rachel R. Kelz, MD, Giorgos C. Karakousis, MD, Douglas L. Fraker, MD

Published in: Annals of Surgical Oncology | Issue 1/2015

ABSTRACT

Background

Pheochromocytomas are rare neuroendocrine tumors. With the widespread use of cross-sectional imaging, increasing numbers are identified incidentally, but their clinicopathologic traits have been incompletely characterized.

Methods

We performed a retrospective cohort study of patients who underwent initial adrenalectomy for pheochromocytoma (1997–2014). Patients were classified as identified by guided investigation (GIP) if imaging was performed for symptoms or surveillance and as incidentally identified pheochromocytomas (IIP) if imaging was performed for other indications. Student’s t test, Chi square test, or rank-sum tests were used as appropriate.

Results

Of 126 patients, 47 % were IIP (n = 59). IIP patients had more nonspecific symptoms, including abdominal or back pain (39.0 vs. 6.0 %, p < 0.001), but lower rates of classic symptoms, such as hypertension (54.2 vs. 77.6 %, p = 0.005), palpitations or arrhythmias (18.9 vs. 50.0 %, p = 0.001), flushing or diaphoresis (25.4 vs. 46.3 %, p = 0.015), and headache (20.3 vs. 44.8 %, p = 0.004). IIP was associated with lower median 24-hour urine metanephrine (2102 vs. 7299 μg, p = 0.020), normetanephrine (2253 vs. 4383 μg, p = 0.005), and epinephrine (23 vs. 116 μg, p = 0.004) levels. Histopathology demonstrated no difference between IIP and GIP in malignant traits, including extraadrenal extension (8.6 vs. 12.3 %, p = 0.568), capsular invasion (26.9 vs. 20.3 %, p = 0.133), lymphovascular invasion (25.0 vs. 24.6 %, p = 0.264), and necrosis (32.4 vs. 20.0 %, p = 0.224). Rates of malignancy were equivalent (5.1 vs. 6.0 %, p = 0.862) between IIP and GIP cohorts.

Conclusions

Half of patients presenting for surgical resection of pheochromocytoma were identified incidentally. These patients had equivalent rates of malignancy and pathologic traits associated with malignant potential and require definitive evaluation and early surgical referral.

Lenders JW, Eisenhofer G, Mannelli M, Pacak K. Phaeochromocytoma. Lancet. 2005; 366:665–75.CrossRef

Beard CM, Sheps SG, Kurland LT, Carney JA, Lie JT. Occurrence of pheochromocytoma in Rochester, Minnesota, 1950 through 1979. Mayo Clinic Proc. 1983; 58:802–4.

Walther MM, Keiser HR, Linehan WM. Pheochromocytoma: evaluation, diagnosis, and treatment. World J Urol. 1999; 17:35–9.PubMedCrossRef

Krane NK. Clinically unsuspected pheochromocytomas. Experience at Henry Ford Hospital and a review of the literature. Arch Intern Med. 1986; 146:54–7.PubMedCrossRef

Amar L, Servais A, Gimenez-Roqueplo AP, Zinzindohoue F, Chatellier G, Plouin PF. Year of diagnosis, features at presentation, and risk of recurrence in patients with pheochromocytoma or secreting paraganglioma. J Clin Endocrinol Metab. 2005; 90:2110–6.PubMedCrossRef

van Berkel A, Lenders JW, Timmers HJ. Diagnosis of endocrine disease: biochemical diagnosis of phaeochromocytoma and paraganglioma. Eur J Endocrinol. 2014; 170:R109–19.PubMedCrossRef

Mantero F, Terzolo M, Arnaldi G, et al. A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology. J Clin Endocrinol Metab. 2000;85:637–44.PubMed

Mannelli M, Lenders JW, Pacak K, Parenti G, Eisenhofer G. Subclinical phaeochromocytoma. Best Pract Res Clin Endocrinol Metab. 2012; 26:507–15.PubMedCentralPubMedCrossRef

Kopetschke R, Slisko M, Kilisli A, et al. Frequent incidental discovery of phaeochromocytoma: data from a German cohort of 201 phaeochromocytoma. Eur J Endocrinol. 2009; 161:355–61.PubMedCrossRef

10.

Ayala-Ramirez M, Feng L, Johnson MM, et al. Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators. J Clin Endocrinol Metab. 2011; 96:717–25.PubMedCrossRef

11.

John H, Ziegler WH, Hauri D, Jaeger P. Pheochromocytomas: can malignant potential be predicted? Urology. 1999;53:679–83.PubMedCrossRef

12.

O’Riordain DS, Young WF Jr, Grant CS, Carney JA, van Heerden JA. Clinical spectrum and outcome of functional extraadrenal paraganglioma. World J Surg. 1996; 20:916–21; discussion 922.

13.

Linnoila RI, Keiser HR, Steinberg SM, Lack EE. Histopathology of benign versus malignant sympathoadrenal paragangliomas: clinicopathologic study of 120 cases including unusual histologic features. Hum Pathol. 1990; 21:1168–80.PubMedCrossRef

14.

Strasberg SM, Linehan DC, Hawkins WG. The accordion severity grading system of surgical complications. Ann Surg. 2009;250:177–86.PubMedCrossRef

15.

Thompson LD. Pheochromocytoma of the Adrenal gland Scaled Score (PASS) to separate benign from malignant neoplasms: a clinicopathologic and immunophenotypic study of 100 cases. Am J Surg Pathol. 2002; 26:551–66.PubMedCrossRef

16.

Baguet JP, Hammer L, Mazzuco TL, et al. Circumstances of discovery of phaeochromocytoma: a retrospective study of 41 consecutive patients. Eur J Endocrinol. 2004; 150:681–6.PubMedCrossRef

17.

Oshmyansky AR, Mahammedi A, Dackiw A, et al. Serendipity in the diagnosis of pheochromocytoma. J Comput Assist Tomogr. 2013; 37:820–3.PubMedCrossRef

18.

Noshiro T, Shimizu K, Watanabe T, et al. Changes in clinical features and long-term prognosis in patients with pheochromocytoma. Am J Hypertens. 2000;13(1 Pt 1):35–43.PubMedCrossRef

19.

Rodriguez JM, Balsalobre M, Ponce JL, et al. Pheochromocytoma in MEN 2A syndrome. Study of 54 patients. World J Surg. 2008; 32:2520–6.PubMedCrossRef

20.

Haissaguerre M, Courel M, Caron P, et al. Normotensive incidentally discovered pheochromocytomas display specific biochemical, cellular, and molecular characteristics. J Clin Endocrinol Metab. 2013;98:4346–54.PubMedCrossRef

21.

Mazzaglia PJ. Hereditary pheochromocytoma and paraganglioma. J Surg Oncol. 2012;106:580–5.PubMedCrossRef

22.

Neumann HP, Pawlu C, Peczkowska M, et al. Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. JAMA. 2004; 292:943–51.PubMedCrossRef

23.

Gimenez-Roqueplo AP, Favier J, Rustin P, et al. Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas. Cancer Res. 2003; 63:5615–21.PubMed

24.

Plouin PF, Duclos JM, Soppelsa F, Boublil G, Chatellier G. Factors associated with perioperative morbidity and mortality in patients with pheochromocytoma: analysis of 165 operations at a single center. J Clin Endocrinol Metab. 2001; 86:1480–6.PubMed

25.

Russell WJ, Metcalfe IR, Tonkin AL, Frewin DB. The preoperative management of phaeochromocytoma. Anaesth Intensive Care. 1998;26:196–200.PubMed

26.

Parenti G, Zampetti B, Rapizzi E, Ercolino T, Giache V, Mannelli M. Updated and new perspectives on diagnosis, prognosis, and therapy of malignant pheochromocytoma/paraganglioma. J Oncol. 2012; 2012:872713.PubMedCentralPubMedCrossRef

27.

Goffredo P, Sosa JA, Roman SA. Malignant pheochromocytoma and paraganglioma: a population level analysis of long-term survival over two decades. J Surg Oncol. 2013;107:659–64.PubMedCrossRef

28.

Fishbein L, Orlowski R, Cohen D. Pheochromocytoma/paraganglioma: review of perioperative management of blood pressure and update on genetic mutations associated with pheochromocytoma. J Clin Hypertens (Greenwich). 2013;15:428–34.CrossRef

29.

Wu D, Tischler AS, Lloyd RV, et al. Observer variation in the application of the Pheochromocytoma of the Adrenal Gland Scaled Score. Am J Surg Pathol. 2009; 33:599–608.PubMedCrossRef

Title: Clinicopathologic Characteristics of Incidentally Identified Pheochromocytoma
Authors: Heather Wachtel, MD
Isadora Cerullo, BA
Edmund K. Bartlett, MD
Robert E. Roses, MD
Debbie L. Cohen, MD
Rachel R. Kelz, MD
Giorgos C. Karakousis, MD
Douglas L. Fraker, MD
Publication date: 01-01-2015
Publisher: Springer US
Published in: Annals of Surgical Oncology / Issue 1/2015
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-014-3933-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Clinicopathologic Characteristics of Incidentally Identified Pheochromocytoma

ABSTRACT

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

ABSTRACT

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2015

Low Infiltration of Peritumoral Regulatory T Cells Predicts Worse Outcome Following Resection of Colorectal Liver Metastases

Less Remains Better: Morbidity After Axillary Surgery

Prognostic Value of Extracapsular Invasion of Axillary Lymph Nodes Combined with Peritumoral Vascular Invasion in Patients with Breast Cancer

Proper Timing of Adjuvant Chemotherapy Affects Survival in Patients with Stage 2 and 3 Gastric Cancer

Breast Conservation in the Setting of Contemporary Multimodality Treatment Provides Excellent Outcomes for Patients with Occult Primary Breast Cancer

Surgical Patterns of Care in Patients with Invasive Breast Cancer Treated with Neoadjuvant Systemic Therapy and Breast Magnetic Resonance Imaging: Results of a Secondary Analysis of TBCRC 017